Gubra’s GAN DIO-MASH mouse model has been top-ranked by the LITMUS¹ consortium for its human proximity score. The LITMUS consortium has evaluated a wide variety of preclinical MASH models using two key parameters, metabolic significance and ability to induce fibrosis. In this evaluation, GAN DIO-MASH mouse model has received the highest human proximity score, which is one of the key indicators of clinical translatability. The GAN DIO-NASH mouse model is readily available for your tailored study.
Since its introduction in 2019, the GAN DIO-MASH mouse model has become an industry-leading gold standard model of liver biopsy-confirmed MASH. The GAN DIO-NASH mouse recapitulates the natural history and hallmarks of NASH with progressive fibrosis and hepatocellular carcinoma burden.
¹LITMUS is a consortium that consists of internationally recognized experts with substantial expertise in metabolic dysfunction–associated steatohepatitis (MASH). The pioneering European research project aims to develop, validate and qualify better biomarkers diagnostic tests for metabolic dysfunction-associated fatty liver disease (MAFLD) and identify those most at risk for developing MASH and liver scarring.
Discover more about on our GAN DIO-MASH model:
- Download the poster ‘Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of NASH’ : here
- Download the publication ‘Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH‘ : here